• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of and finding treatments for complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

Postural tachycardia syndrome - 33% of POTS patients have organ-specific autoantibodies...

Bob

Senior Member
Messages
16,455
Location
England (south coast)
New autoimmune research on POTS from the 25th International Symposium on the Autonomic Nervous System:

KEY FINDING: 33% of POTS patients have organ-specific autoantibodies, suggesting an autoimmune basis for at least 1/3 of patients.

CITATION: W. Singer, C.J. Klein, P.A. Low, V.A. Lennon. Autoantibodies in the postural tachycardia syndrome. Clinical Autonomic Research (2014): 24:199-243.

Read more here:
https://www.facebook.com/kathryn.stephens.9/posts/866813560010021

Dysautonomia International said:
DETAILS: Mayo Clinic researchers reviewed their patient charts for individuals who fulilled the criteria for POTS between 2001 and 2006, who had stored serum available for testing. 33 patients were included in the study, ranging in age from 16 to 52, median age 27, 82% female. Mayo tested this serum for organ-specific autoantibodies (neural cation channels, thyroglobulin, thyroperoxidase, GAD65, neural-specific plasma membrane cytoplasmic and nuclear antibodies, and skeletal/heart muscle sarcomeric antibodies). At least one of these antibodies was found in 33% of POTS patients included in the study, and 15% had more than one of these autoantibodies. Only 4.4% of 161 healthy adult controls had one of these antibodies. The researchers concluded that these serological findings and female predominance of POTS support an organ-specific autoimmune basis for at least one third of cases (note – other patients may have non-organ specific antibodies or other organ-specific antibodies which were not tested in this study so the percentage of autoimmune cases could be higher). Mayo researchers recommend a focused investigation of serum from a larger number of patients with POTS to ascertain the freuquent and nature of neural-specific antibodies with pathological potential in POTS.
 

alex3619

Senior Member
Messages
13,810
Location
Logan, Queensland, Australia
Yes, but with one caveat. Trace amounts of organ specific antibodies are not likely to be highly debilitating. Antibody titres will be important in a follow up study.

However a number of these will affect neurological capacity, and we simply do not know enough to predict the result of even low levels. So nervous system targeting autoantibodies could be dangerous at even small levels.